Osthole accelerates osteoporotic fracture healing by inducing the osteogenesis–angiogenesis coupling of BMSCs via the Wnt/β‐catenin pathway

Abstract Osthole, a natural coumarin derivative, has been shown to have multiple pharmacological activities. However, its effect on osteoporotic fracture has not yet been examined. This research was designed to explore the unknown role and potential mechanism of osthole on osteoporotic fracture healing. We first evaluated the osteogenic and angiogenic abilities of osthole. Then angiogenesis‐related assays were conducted to investigate the relationship between osteogenesis and angiogenesis, and further explore its molecular mechanism. After that, we established osteoporotic fracture model in ovariectomy‐induced osteoporosis rats and treated the rats with osthole or placebo. Radiography, histomorphometry, histology, and sequential fluorescent labeling were used to evaluate the effect of osthole on osteoporotic fracture healing. In vitro research revealed that osthole promoted osteogenesis and up‐regulated the expression of angiogenic‐related markers. Further research found that osthole couldn't facilitate the angiogenesis of human umbilical vein endothelial cells in a direct manner, but it possessed the ability to induce the osteogenesis–angiogenesis coupling of bone marrow mesenchymal stem cells (BMSCs). Mechanistically, this was conducted through activating the Wnt/β‐catenin pathway. Subsequently, using ovariectomy‐induced osteoporosis tibia fracture rat model, we observed that osthole facilitated bone formation and CD31 hi EMCN hi type H‐positive capillary formation. Sequential fluorescent labeling confirmed that osthole could effectively accelerate bone formation in the fractured region. The data above indicated that osthole could accelerate osteoporotic fracture healing by inducing the osteogenesis–angiogenesis coupling of BMSCs via the Wnt/β‐catenin pathway, which implied that osthole may be a potential drug for treating osteoporosis fracture.